Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials

E-ISSN： 1873-5592|13|12|1525-1534

ISSN： 1389-4501

Source： Current Drug Targets, Vol.13, Iss.12, 2012-11, pp. : 1525-1534

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Surrogate Efficacy Endpoints in Oncology Trials

By Markman Maurie

Pharmaceutical Medicine, Vol. 23, Iss. 5-6, 2009-10 ,pp. : 283-287

Adis International

Access to resources Recommend Favorite

A Bayesian Approach for Dose-Escalation in a Phase I Clinical Trial Incorporating Pharmacodynamic Endpoints

By Whitehead John

Journal of Biopharmaceutical Statistics, Vol. 17, Iss. 6, 2007-11 ,pp. : 1117-1129

Taylor & Francis Ltd

Access to resources Recommend Favorite

An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

By Su Zheng

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 397-403

Adis International

Access to resources Recommend Favorite

Overactive bladder treatments in early phase clinical trials

By Colli Enrico Digesu Giuseppe Alessandro Olivieri Lorenza

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-06 ,pp. : 999-1007

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of Early Efficacy Endpoints for Proof-of-Concept Trials

By Chen Cong

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 2, 2013-03 ,pp. : 413-424

Taylor & Francis Ltd

Access to resources Recommend Favorite